Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) said on Wednesday that it has entered into an agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to provide up to USD250m in research and development funding for litifilimab, a first-in-class biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab has demonstrated proof-of-concept and a well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. It has the potential to be the first targeted biologic approved for CLE, a disease with no currently available treatments.
Biogen expects Phase 3 trial results between 2026 and 2027.
Under the deal, Royalty Pharma will provide funding over six quarters in exchange for regulatory milestones and mid-single-digit royalties on global sales.
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial
Celltrion's OMLYCLO receives US FDA approval
RiboX Therapeutics doses first patient in RXRG001 first-in-human Phase I/IIa clinical trial
Doer Bio completes DR10624phase two clinical study enrolment
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Kancera and Recardio sign letter of intent for licensing agreement
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada
Integral Molecular reports first patient dosed in CTIM-76 Phase 1 clinical trial
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals submits Phase Ib clinical trial application for CS5001 in Australia
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio